Monday, Esperion Therapeutics  and Otsuka Pharmaceutical Co Ltd announced that the primary endpoint in the Phase 3 trial in Japan for bempedoic acid for hypercholesterolemia was achieved. 

The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.

Related: Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars.

The Phase 3 trial was conducted in 96 patients with high LDL cholesterol and in whom satins have insufficient effect or cannot be tolerated. 

In the preliminary results, the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo group, demonstrating positive outcomes with statistical significance compared to placebo (p